Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Exelixis, inc. symbols : TAK save search
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.47 -0.21% -1.11% 20K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.55 -0.12% -0.06% 240K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.78 -3.82% 2.3% 19
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.47 -6.72% -7.2% 730K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.03%
H: 1.69%
C: 1.32%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.68%
H: 1.66%
C: 1.49%
opdivo renal trial cell carcinoma nivolumab
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-02-07 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.89%
CTLT | $55.95 -0.14% -0.18% 1.6M
|
Health Technology
|
| O: 3.66%
H: 4.45%
C: 3.07%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.64%
H: 1.11%
C: 0.76%
year financial update results
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.42%
H: 0.48%
C: -0.41%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -1.91%
osmic-312 liver trial cancer phase 3
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Published: 2022-02-17 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.36%
C: -0.07%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.15%
H: 0.41%
C: -0.16%
MSFT | News 4 | $409.06 0.37% -0.54% 11M
|
Technology Services
|
| O: -1.05%
H: 0.15%
C: -1.9%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.42%
H: 0.89%
C: -3.47%
financial results ces results
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
Published: 2022-02-15 (Crawled : 08:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.4%
H: 0.53%
C: 0.46%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: 0.86%
H: 3.36%
C: 2.29%
cabometyx opdivo trial
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
asco cancer colorectal cancer immunotherapy
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
Published: 2022-01-05 (Crawled : 14:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.07%
H: 0.8%
C: -1.67%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: -3.43%
ntact-03 renal trial cel phase 3 enroll cell carcinoma
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.69%
H: 0.83%
C: -1.02%
lung cancer cancer phase 3 trial enroll
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
Published: 2021-09-20 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -1.64%
H: 1.34%
C: -1.29%
results cancer phase 3 trial
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-09-17 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
EXEL | $23.71 1.8% 1.73% 12
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
fda fda approval cancer approval
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 17M
|
TSLA | News | $162.13 12.06% 10.13% 170M
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.